MLC901(NeuroAiD II)用于中度创伤性脑损伤患者安全性与疗效的方案:一项随机双盲安慰剂对照试验(ANDROMEDA)
本研究为多中心随机双盲安慰剂对照试验,计划纳入120例接受标准治疗的中度创伤性脑损伤成人患者,比较MLC901与安慰剂治疗6个月并随访3个月。主要终点为6个月时扩展格拉斯哥结局量表(GOS-E)评分,同时评估认知、功能、情绪、生活质量及脑肿胀等指标。研究预期MLC901组在功能和认知结局方面有显著改善,并认为既往研究样本量小,本研究将更明确地确立MLC901的作用。
要点
- 多中心随机双盲安慰剂对照试验,计划纳入120例中度创伤性脑损伤成人患者。
- MLC901与安慰剂对照,治疗6个月,随后随访3个月,总研究时长9个月。
- 主要终点为6个月时扩展格拉斯哥结局量表(GOS-E)评分。
核心结论
- 研究预期MLC901组在功能和认知结局方面有显著改善,并认为本研究将更明确地确立MLC901在中度创伤性脑损伤患者功能和认知结局改善中的作用。
研究设计与样本
- 多中心随机双盲安慰剂对照试验,计划纳入120例接受标准治疗的中度创伤性脑损伤成人患者,分为MLC901组与安慰剂组2个臂。
- 治疗期为6个月,随后随访3个月,研究总时长为9个月。
关键数值与推荐
- 主要终点为6个月时扩展格拉斯哥结局量表(GOS-E)评分。
- 其他评估包括6个月死亡率,以及1、3、6、9个月时的GOS-E、格拉斯哥昏迷量表、蒙特利尔认知评估菲律宾版、额叶评估成套测验冲突指令与Go-No-Go、Rivermead脑震荡后症状问卷、Barthel指数、医院焦虑抑郁量表与健康相关生活质量(EQ-5D)。
- 基线与1周、2周时记录脑肿胀,并监测不良事件与药物依从性。
局限性
- 既往关于MLC901用于中度创伤性脑损伤成人患者的研究显示阳性结果,但这些研究受患者数量少的限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Traumatic brain injury (TBI) remains a leading cause of death and disability, affecting approximately 69 million individuals each year worldwide. A significant portion of TBI research has focused on treatments for neuroprotection and/or neurorecovery, with most failing to transition to successful clinical applications despite promising animal/in vitro study results. MLC901 (NeuroAiD II), with origins from a traditional Chinese medicine, has been shown to exhibit both neuroprotective and neuroregenerative properties in in vitro and animal studies for stroke and TBI. Clinical trials have demonstrated its safety with significant improvements in some functional outcome and cognitive domain measures. The objective of this study is to determine the efficacy and safety of MLC901 (NeuroAiD II) vs placebo in adult patients with moderate TBI. METHODS: This is a multicenter randomized double-blind placebo-controlled trial that aims to enroll 120 adult patients with moderate TBI receiving standard of care in 2 arms: MLC901 vs placebo for a treatment period of 6 months with a further follow-up of 3 months. The total duration of the study is 9 months. The primary end point is Glasgow Outcome Scale Extended (GOS-E) at 6 months. Other assessments include mortality at 6 months, GOS-E, Glasgow Coma Scale, Montreal Cognitive Assessment Filipino Version, Frontal Assessment Battery Conflicting Instructions and Go-No-Go, Rivermead Post-Concussion Symptom Questionnaire, Barthel Index, Hospital Anxiety and Depression Scale, and Health related Quality of life (EQ-5D) at 1, 3, 6, and 9 months. Cerebral swelling at baseline and at 1 and 2 weeks will also be documented. Adverse events and drug compliance will also be monitored. EXPECTED OUTCOMES: We expect to find a significant improvement in functional and cognitive outcomes in patients who were given MLC901. DISCUSSION: Previous studies on the effect of MLC901 in adult patients with moderate TBI showed positive results; However, these studies are limited by the small number of patients. This study will establish a more definitive role of MLC901 in improving functional and cognitive outcomes in patients with moderate TBI.
引用
- Chua AE, Yacapin VJ, Manalo GL, et al. Protocol for Safety and Efficacy of MLC901 (NeuroAiD II) in Patients With Moderate Traumatic Brain Injury: A Randomized Double-Blind Placebo-Controlled Trial (ANDROMEDA). Neurosurgery. 2023. PMID: 37129384. doi:10.1227/neu.0000000000002512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。